Loading...

Explore Our Categories

Latest Post

Latest News

Keenova Reports Third Quarter 2026 Financial Results
Ny Newsly

Keenova Reports Third Quarter 2026 Financial Results

Continued Strong Performance Driven by Growth in Acthar® Gel1 and XIAFLEX®2 XIAFLEX Pipeline Advances: Plantar Fibromatosis sBLA Submission Expected in First Quarter 2027, Hammer Toe Phase 3 Study…

Scroll to Top